Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxALZ-801 Trial Results Announced: A Breakthrough in Alzheimer’s Treatment?

On September 20, 2022, Alzheon Inc. announced promising results from its phase 2 trial of oral ALZ-801 (valiltramiprosate) in patients with early AD. The drug decreased p-tau181 levels, reduced brain atrophy, and improved cognitive skills in the trial.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form